Rikke Olesen

Rikke Olesen

Auto-generated profile, based on publicly available information

Rikke Olesen

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in The Lancet HIV
Verified
Journal Article
Closed access
TRThomas A Rasmussen
Thomas A Rasmussen
MTMartin Tolstrup
Martin Tolstrup
CBChristel R Brinkmann
Christel R Brinkmann
RORikke Olesen
Rikke Olesen
CEChristian Erikstrup
Christian Erikstrup
OSOle S. Søgaard
Ole S. Søgaard

17 September 2015 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
OSOle S. Søgaard
Ole S. Søgaard
MGMette E. Graversen
Mette E. Graversen
SLSteffen Leth
Steffen Leth
RORikke Olesen
Rikke Olesen
CBChristel R. Brinkmann
Christel R. Brinkmann
MTMartin Tolstrup
Martin Tolstrup
Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HIV-1 latency in humans have yielded mixed results. Here, we report a proof-of-concept phase Ib/IIa trial where 6 aviremic HIV-1 infected adults received intravenous 5 mg/m2 romidepsin (Celgene) once weekly for 3 weeks while maintaining ART. Lymphocyte histone H3 acetylation, a cellular measure of the pharmacodynamic response to romidepsin, increased rapidly (maximum fold range: 3.7–7.7 relative to baseline) within the first hours following each romidepsin administration. Concurrently, HIV-1 transcription quantified as copies of cell-associated un-spliced HIV-1 RNA increased significantly from baseline during treatment (range of fold-increase: 2.4–5.0; p = 0.03). Plasma HIV-1 RNA increased from <20 copies/mL at baseline to readily quantifiable levels at multiple post-infusion time-points in 5 of 6 patients (range 46–103 copies/mL following the second infusion, p = 0.04). Importantly, romidepsin did not decrease the number of HIV-specific T cells or inhibit T cell cytokine production. Adverse events (all grade 1–2) were consistent with the known side effects of romidepsin. In conclusion, romidepsin safely induced HIV-1 transcription resulting in plasma HIV-1 RNA that was readily detected with standard commercial assays demonstrating that significant reversal of HIV-1 latency in vivo is possible without blunting T cell-mediated immune responses. These finding have major implications for future trials aiming to eradicate the HIV-1 reservoir. clinicaltrials.gov NTC02092116 One proposed way of curing HIV is to activate virus transcription and kill latently infected cells while the presence of antiretroviral therapy prevents spreading the infection. Induction of global T cell activation by mitogenic or other potent activators effectively reverses HIV-1 from latency ex vivo, but such compounds are generally too toxic for clinical use. Therefore, investigating the capacity of small molecule latency reversing agents to induce production of virus without causing global T cell activation has been a top research priority for scientists in recent years. In the present clinical trial, we demonstrate that significant viral reactivation can be safely induced using the depsipeptide romidepsin (HDAC inhibitor) in long-term suppressed HIV-1 individuals on antiretroviral therapy. Following each romidepsin infusion, we observed clear increases in lymphocyte H3 acetylation, HIV-1 transcription, and plasma HIV-1 RNA. Importantly, this reversal of HIV-1 latency could be measured using standard clinical assays for detection of plasma HIV-1 RNA. Furthermore, romidepsin did not alter the proportion of HIV-specific T cells or inhibit T cell cytokine production which is critically important for future trials combining HDAC inhibitors with interventions (e.g. therapeutic HIV-1 vaccination) designed to enhance killing of latently infected cells.

1 January 2012 in Journal of Virology
Verified
Journal Article
Closed access
PDPaul W. Denton
Paul W. Denton
RORikke Olesen
Rikke Olesen
SCShailesh K. Choudhary
Shailesh K. Choudhary
NANancy M. Archin
Nancy M. Archin
AWAngela Wahl
Angela Wahl
JGJ. Victor Garcia
J. Victor Garcia
Here we demonstrate that a combination of tenofovir, emtricitabine, and raltegravir effectively suppresses peripheral and systemic HIV replication in humanized BLT mice. We also demonstrate that antiretroviral therapy (ART)-treated humanized BLT mice harbor latently infected resting human CD4 + T cells that can be induced ex vivo to produce HIV. We observed that the levels of infected resting human CD4 + T cells present in BLT mice are within the range of those observed circulating in patients undergoing suppressive ART. These results demonstrate the potential of humanized BLT mice as an attractive model for testing the in vivo efficacy of novel HIV eradication strategies.

1 October 2016 in The Lancet HIV
Verified
Journal Article
Closed access
SLSteffen Leth
Steffen Leth
MSMariane H Schleimann
Mariane H Schleimann
SNSara K Nissen
Sara K Nissen
JHJesper F Højen
Jesper F Højen
RORikke Olesen
Rikke Olesen
OSOle S. Søgaard
Ole S. Søgaard

5 July 2007 in Genes & Immunity
Verified
Journal Article
Closed access
ROR Olesen
R Olesen
Christian WejseChristian Wejse
Christian Wejse
DVD R Velez
D R Velez
CBCyrille BIsseye
Cyrille BIsseye
MSM Sodemann
M Sodemann
GSG Sirugo
G Sirugo

22 September 2009 in Human Genetics
Verified
Journal Article
Closed access
PDF file
DVDigna Rosa Velez
Digna Rosa Velez
Christian WejseChristian Wejse
Christian Wejse
MSMartin E. Stryjewski
Martin E. Stryjewski
EAEduardo Abbate
Eduardo Abbate
WHWilliam F. Hulme
William F. Hulme
WSWilliam K. Scott
William K. Scott